Research

Monoclonal antibody “cocktail” blocks COVID-19 variants: study

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.

Targeting glucagon action in diabetes

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.

Biostatistician DeMets set for next Discovery Lecture

David DeMets, PhD, known for his work on statistical methods to monitor interim clinical trial data for early evidence of benefit or harm, will deliver the next web-based Discovery Lecture.

Chikungunya antibody identified at VUMC moves forward

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Case Western’s Jain to discuss age-related disorders at next Discovery Lecture

Mukesh Jain, MD, vice dean for Academic Affairs and Medical Sciences and professor of Medicine at Case Western Reserve University, will discuss the discovery of aging-related disease genes and pathways during the next web-based Discovery Lecture.

Calcification after severe injury

Vanderbilt researchers have linked bone-related complications of severely injured patients — findings that could help minimize these complications.

1 36 37 38 39 40 210